Buried Science

Remedies › Ivermectin › Cancer · All remedies for cancer

Ivermectin and cancer: what the evidence says

Animal studies and case reports suggest ivermectin slows cancer cells and tumors in mice, but no controlled trial in people with cancer has reported results, the largest human report was retracted, and published cases include serious poisoning.

2/5 Preliminary

Animal studies, and at most single case reports in people. No controlled human trial on this outcome. How we score

A research summary, not a substitute for treatment. If you or someone you care for has cancer, talk to the oncologist before adding any supplement, and do not delay or replace treatment.

PubMed lists 287 papers on ivermectin and cancer once parasite, veterinary and COVID-19 papers are set aside, and about 227 of them are lab or animal studies. Most report that it slows or kills cancer cells, with proposed targets including the Wnt/beta-catenin pathway, the PAK1 enzyme and the P-glycoprotein drug pump.

No controlled trial in people with cancer has published results. A US trial of ivermectin with immunotherapy for metastatic triple-negative breast cancer (34 planned) has been recruiting since 2023 with nothing posted, and a University of Florida trial (80 planned) has not yet started.

The largest human report, a 2026 survey of 197 people prescribed ivermectin with mebendazole through a telemedicine service, said 48% of those followed up reported regression or no evidence of disease. The journal retracted it in October 2026 over methodological and analytical problems, so we do not count it.

The remaining human evidence is six case reports: three describe improvement alongside other treatments or with no comparison, one a short-lived response, and two serious harm (liver injury; seizures and respiratory failure). We read all 35 records the search flagged as possible human studies; 22 were about something else.

The evidence ladder higher rungs count for more
  1. Meta-analyses of trialspooled randomized trials0
  2. Human studiestrials and population studies0
  3. Case reportssingle people6
  4. Animal studiesmostly rodents76
  5. Lab studiescells, test tubes151

The studies in people, read one by one

ResultTypeWhat they didWhat they found
MixedCase report, 2026
1 people		Case report, metastatic melanoma, self-directed ivermectin + fenbendazole instead of standard treatment
Measured: Tumor response and circulating tumor DNA		Tumor DNA in the blood fell from 2.04 to 0.18 MTM/mL as the disease shrank, then rose to 0.93 as the main node grew again; the authors say spontaneous immune regression is at least as plausible as a drug effect. PubMed 42745863
PositiveCase report, 2026
6 people		Case series, six stage IV cancers given ivermectin, mebendazole, praziquantel, niclosamide and antifungals chosen by an electro-acupuncture reading
Measured: Survival and disease progression		The author reports survival beyond expected prognosis in all six, including one breast cancer remission and a PSA fall from 32 to 0.3; there is no comparison group, several drugs were combined, and the author's affiliation is a company named Your Energy Systems. PubMed 42491797
PositiveCase report, 2026
1 people		Case report, stage IV HR-positive breast cancer, chemotherapy plus fasting, ketogenic diet, hyperthermia, hyperbaric oxygen and six repurposed drugs including ivermectin
Measured: Tumor burden on PET-CT		Tumor burden was reduced at 3 months; she was also receiving docetaxel, doxorubicin and cyclophosphamide, so no single part of the protocol can be credited. PubMed 42100430
PositiveCase report, 2022
3 people		Three patients given dichloroacetate, omeprazole (with or without tamoxifen) and ivermectin
Measured: Cancer-related symptoms		The authors, from a Tokyo company, report that the combination dramatically relieved symptoms in three patients with cancer or sarcoma; the abstract gives no tumor measurements. PubMed 35265417
NegativeCase report, 2026
1 people		Case report, prostate cancer, veterinary fenbendazole and ivermectin alternated daily for 3 months on advice from online groups
Measured: Liver injury		Severe liver injury (ALT 1,764 U/L, bilirubin 12.9 mg/dL), rated highly probable drug-related; liver tests normalized within 6 weeks of stopping both. PubMed 42299164
NegativeCase report, 2026
1 people		Case report, 73-year-old with metastatic breast cancer who self-administered high-dose ivermectin based on online information
Measured: Toxicity		She developed confusion, generalized seizures and respiratory failure needing a ventilator, and recovered fully within 48 hours. PubMed 42170801

Where the sources agree, and where they don’t

1 of 7 kinds of source point toward a benefit, 1 toward no effect or harm, 3 are mixed, and 2 have no data yet. Agreement between independent kinds of evidence matters more than the number of papers in any one of them.

Kind of sourcePoints toDetail
Lab and animal studiesPositiveabout 227 papers, mostly positive in cells and mice
Controlled human trialsNo data1 recruiting since 2023, 1 not started; no results
Case reports in PubMedMixed3 improvements, all uncontrolled or with other treatment; 1 short-lived
Largest human surveyNo data197 people, 48% reported regression; retracted October 2026
Toxicity case reportsNegativeliver injury; seizures and respiratory failure
FDA reportsMixed41 reports for cancer use, 24 serious; 7 coded 'effective', 6 'ineffective'
Public reportsMixed10 of 20 say it helped, nearly all with hormone therapy or other treatment

Beyond Google: 8 findings about Ivermectin from trial registries, FDA reports and patent offices that a normal search rarely shows. See them

What people report

We read public first-person posts and counted every outcome, good or bad. 20 reports about this condition, read on 2026-10-28; 1 mention side effects.

  • 10Helped
  • 1No effect
  • 1Got worse
  • 4Mixed
  • 4Too early

Why these counts prove nothing on their own: people who post are not a random sample, most take other treatments at the same time, and nobody checks the diagnosis. We show them because they tell researchers what to test next.

Read all 20 reports
  • Worse Took 70 mg ivermectin daily with mebendazole while waiting for chemotherapy; side effects were bad enough that he stopped after five days. Side effects: dizziness, brain fog, nausea, ringing in the ears. HealthUnlocked, 2026-03 (Dose far above approved human doses; outcome is side effects, not cancer response.)
  • Helped Takes about 1 mg/kg five days a week as part of a combined approach and says the combination is working for him. HealthUnlocked, 2026-03 (On Pluvicto at the same time; no numbers given.)
  • No effect After about four years with stage 4 disease, says ivermectin did not work for him and advises staying on standard treatment. HealthUnlocked, 2026-03 (No dose, dates or numbers given.)
  • Helped Self-medicating with ivermectin alongside hormone therapy; says PSA is holding at 0.01. HealthUnlocked, 2021-08 (PSA was measured while on hormone therapy, which alone can explain it.)
  • Helped Took fenbendazole and ivermectin about 1 mg/kg daily; says PSA did not rise for 8 months and fell for the first time. HealthUnlocked, 2025-06 (Started before radiotherapy, but the timeline against other treatment is unclear.)
  • Mixed Took both for several months; PSA stopped rising in the first month only, then kept progressing. HealthUnlocked, 2025-06 (Says it may not suit stage 4 disease; no numbers given.)
  • Helped Took both for six months and says PSA fell, with no side effects or changes in his liver tests. HealthUnlocked, 2025-06 (Also on relugolix and radiotherapy, which lower PSA on their own.)
  • Helped Takes 4-day cycles of 12 mg ivermectin and fenbendazole each month and credits them with keeping his CEA marker near undetectable after colon surgery. HealthUnlocked, 2025-06 (Marker after surgery that removed the tumor; does not think they help his prostate cancer.)
  • Mixed PSA fell from 13.36 to 12.22 on high-dose ivermectin, fenbendazole, keto and fasting; elsewhere he says it later reversed and he began hormone therapy. HealthUnlocked, 2025-01 (Small PSA change; switched to standard treatment.)
  • Helped Wife reports his urinary symptoms disappeared within two weeks and PSA fell from 4.7 to 3.7 between February and April. HealthUnlocked, 2025-04 (Caregiver report; surgery and hormone therapy had been recommended, unclear what he received.)
  • Mixed After triplet therapy he stopped hormone drugs for 12 to 36 mg ivermectin daily; a PSMA scan was clear, PSA rose slightly. HealthUnlocked, 2025-06 (Caregiver report; the clear scan followed standard triplet therapy.)
  • Too early Taking fenbendazole and ivermectin and waiting for his next PSA test to see whether they work. HealthUnlocked, 2025-06 (No result yet.)
  • Too early Takes horse-paste ivermectin about three days a week; PSA hit a new low but he is also on hormone therapy and draws no conclusion. HealthUnlocked, 2021-06 (Says elsewhere he has used it only alongside standard treatment.)
  • Helped Taking 18 to 30 mg of liquid ivermectin weekly for over a year; PSA has stayed at 0.02 for six months off hormone therapy. HealthUnlocked, 2024-08 (He says he does not know whether ivermectin is the reason.)
  • Helped Says PSA fell from 6 to 0.9 off hormone therapy and 0.75 to 0.11 on it, taking 48 mg every other day for 12 days. HealthUnlocked, 2022-06 (Short course; part of the fall was on hormone therapy.)
  • Helped Off hormone therapy, PSA had reached 2,658; within three months of ivermectin and fenbendazole it fell to 164, rose when he lapsed, then fell again. HealthUnlocked, 2026-07 (No medical follow-up or scans; very large PSA swings.)
  • Helped Takes ivermectin with other repurposed drugs; says PSA has stayed around 4 to 5 and MRI lesions stopped growing. HealthUnlocked, 2025-01 (Low-risk disease under surveillance; several drugs at once.)
  • Too early Two months into an ivermectin protocol and waiting for scans and blood work. HealthUnlocked, 2025-06 (No result yet.)
  • Too early Took prescribed ivermectin for three days for COVID-19; lymphocyte count went from about 30,000 to 26,500, which he thought might be coincidence. HealthUnlocked, 2021-05 (A forum administrator notes a drop this size is common in CLL.)
  • Mixed Weekly ivermectin from mid-2021; lymphocyte counts that had been doubling leveled off near 27,000, but his haematologist later started treatment anyway. HealthUnlocked, 2022-02 (Not taken for cancer; standard treatment followed.)

Every other paper we found

PubMed returned 287 papers for this search on 2026-10-28. We read the human studies above ourselves. The rest are sorted by type automatically from PubMed's labels, which are sometimes wrong. We removed 22 papers that only share a word with this search.

Animal studies 76
  1. Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review. Pharmaceuticals (Basel), 2026
  2. Causes of mortality in koalas autopsied at the University of Melbourne. Aust Vet J, 2025
  3. Antitumor potential of ivermectin against T-cell lymphoma-bearing hosts. Med Oncol, 2025
  4. Targeting EGFR/PI3K/AKT/mTOR and Bax/Bcl-2/caspase3 pathways with ivermectin mediates its anticancer effects against urethane-induced non-small cell lung cancer in BALB/c mice. Tissue Cell, 2025
  5. Transport mechanisms of pesticide mixtures impairing intestinal barrier function in mice. Pestic Biochem Physiol, 2025
  6. Epicatechin attenuates emamectin benzoate-induced liver injury in grass carp by activating Nrf2/GPX4 signaling pathway. Fish Shellfish Immunol, 2025
  7. Ivermectin induces oxidative stress and mitochondrial damage in Haemonchus contortus. Vet Parasitol, 2025
  8. Ferulic acid alleviates cardiac injury by inhibiting avermectin-induced oxidative stress, inflammation and apoptosis. Comp Biochem Physiol C Toxicol Pharmacol, 2025
  9. Doramectin Induces Apoptosis in B16 Melanoma Cells. Anticancer Agents Med Chem, 2025
  10. Ivermectin Synergizes with Modulated Electro-hyperthermia and Improves Its Anticancer Effects in a Triple-Negative Breast Cancer Mouse Model. ACS Pharmacol Transl Sci, 2024
  11. Detection and dynamics of tumor necrosis factor alpha in the diagnosis and treatment of canine heartworm disease. Vet Ital, 2024
  12. New insights into resveratrol attenuates hepatotoxicity in emamectin benzoate-exposed grass carp (Ctenopharyngodon idella) via NO system/NF-κB signaling pathway. Pestic Biochem Physiol, 2024
  13. Pesticide avermectin-induced hepatotoxicity and growth inhibition in carp: Ameliorative capacity and potential mechanisms of quercetin as a dietary additive. Aquat Toxicol, 2024
  14. Ivermectin ameliorates bleomycin-induced lung fibrosis in male rats by inhibiting the inflammation and oxidative stress. Immunopharmacol Immunotoxicol, 2024
  15. Resveratrol improves emamectin benzoate-induced pyroptosis and inflammation of Ctenopharyngodon idellus hepatic cells by alleviating oxidative stress/endoplasmic reticulum stress. Fish Shellfish Immunol, 2023
  16. Neuroprotective effects of ivermectin against transient cerebral ischemia-reperfusion in rats. Metab Brain Dis, 2023
  17. Co-exposure of avermectin and imidacloprid induces DNA damage, pyroptosis, and immune dysfunction in epithelioma papulosum cyprini cells via ROS-mediated Keap1/Nrf2/TXNIP axis. Fish Shellfish Immunol, 2023
  18. Ivermectin Protects Against Experimental Autoimmune Encephalomyelitis in Mice by Modulating the Th17/Treg Balance Involved in the IL-2/STAT5 Pathway. Inflammation, 2023
  19. Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma. Biochem Biophys Res Commun, 2023
  20. The potential effect of Moringa oleifera ethanolic leaf extract against oxidative stress, immune response disruption induced by abamectin exposure in Oreochromis niloticus. Environ Sci Pollut Res Int, 2023
  21. The effect of multiple-dose ivermectin treatment on CD4+/CD8+ and the oxidative stress index in goats with udder viral papillomatosis. Res Vet Sci, 2023
  22. A pilot study of chemotherapy combinations in rats: Focus on mammary cancer treatment in female dogs. Res Vet Sci, 2023
  23. In vitro and in vivo evaluation of the antiviral activity of arctigenin, ribavirin, and ivermectin against viral hemorrhagic septicemia virus infection. Fish Shellfish Immunol, 2023
  24. Ivermectin Attenuates CCl4-Induced Liver Fibrosis in Mice by Suppressing Hepatic Stellate Cell Activation. Int J Mol Sci, 2022
  25. Conservation of Importin α Function in Apicomplexans: Ivermectin and GW5074 Target Plasmodium falciparum Importin α and Inhibit Parasite Growth in Culture. Int J Mol Sci, 2022
  26. Efficacy of ivermectin against colon cancer induced by dimethylhydrazine in male wistar rats. Saudi Pharm J, 2022
  27. Emamectin benzoate induced enzymatic and transcriptional alternation in detoxification mechanism of predatory beetle Paederus fuscipes (Coleoptera: Staphylinidae) at the sublethal concentration. Ecotoxicology, 2021
  28. Neuroprotective effect of hesperidin against emamectin benzoate-induced neurobehavioral toxicity in rats. Neurotoxicol Teratol, 2021
  29. Synthetic Monopartite Peptide That Enables the Nuclear Import of Genes Delivered by the Neurotensin-Polyplex Vector. Mol Pharm, 2020
  30. Inhibition of TMEM16A Ca2+-activated Cl- channels by avermectins is essential for their anticancer effects. Pharmacol Res, 2020
  31. Identification of Functional Transcriptional Binding Sites within Chicken Abcg2 Gene Promoter and Screening Its Regulators. Genes (Basel), 2020
  32. Ivermectin Augments the In Vitro and In Vivo Efficacy of Cisplatin in Epithelial Ovarian Cancer by Suppressing Akt/mTOR Signaling. Am J Med Sci, 2020
  33. Ivermectin inhibits canine mammary tumor growth by regulating cell cycle progression and WNT signaling. BMC Vet Res, 2019
  34. Variation in Local and Systemic Pro-Inflammatory Immune Markers of Wild Wood Mice after Anthelmintic Treatment. Integr Comp Biol, 2019
  35. Genotoxicity and carcinogenicity of ivermectin and amoxicillin in vivo systems. Environ Toxicol Pharmacol, 2019
  36. Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and apoptosis in vitro and in vivo. J Cell Biochem, 2019
  37. Macrocyclic lactones inhibit nasopharyngeal carcinoma cells proliferation through PAK1 inhibition and reduce in vivo tumor growth. Drug Des Devel Ther, 2018
  38. Knockout of a P-glycoprotein gene increases susceptibility to abamectin and emamectin benzoate in Spodoptera exigua. Insect Mol Biol, 2018
  39. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer. Proc Natl Acad Sci U S A, 2017
  40. Fast and simple detection methods for the 4-base pair deletion of canine MDR1/ ABCB1 gene by PCR and isothermal amplification. J Vet Diagn Invest, 2017
  41. Synergism between ivermectin and the tyrosine kinase/P-glycoprotein inhibitor crizotinib against Haemonchus contortus larvae in vitro. Vet Parasitol, 2016
  42. Dysregulated YAP1/TAZ and TGF-β signaling mediate hepatocarcinogenesis in Mob1a/1b-deficient mice. Proc Natl Acad Sci U S A, 2016
  43. A functional model for feline P-glycoprotein. J Vet Pharmacol Ther, 2016
  44. Serotonergic regulation of melanocyte conversion: A bioelectrically regulated network for stochastic all-or-none hyperpigmentation. Sci Signal, 2015
  45. Ivermectin binds to Haemonchus contortus tubulins and promotes stability of microtubules. Int J Parasitol, 2015
  46. Characterization of multidrug transporter-mediated efflux of avermectins in human and mouse neuroblastoma cell lines. Toxicol Lett, 2015
  47. Interaction between anthelmintic treatment and vaccine responses in ponies naturally infected with cyathostomins. Vet Immunol Immunopathol, 2015
  48. Effects of avermectin on immune function and oxidative stress in the pigeon spleen. Chem Biol Interact, 2014
  49. Caenorhabditis elegans: modest increase of susceptibility to ivermectin in individual P-glycoprotein loss-of-function strains. Exp Parasitol, 2013
  50. ATP-P2X7 receptor signaling controls basal and TNFα-stimulated glial cell proliferation. Glia, 2012
  51. Analysis of the effect of the bovine adenosine triphosphate-binding cassette transporter G2 single nucleotide polymorphism Y581S on transcellular transport of veterinary drugs using new cell culture models. J Anim Sci, 2011
  52. Protective effect of abamectin on acute lung injury induced by lipopolysaccharide in mice. Fundam Clin Pharmacol, 2011
  53. Effects of avermectins on neurite outgrowth in differentiating mouse neuroblastoma N2a cells. Toxicol Lett, 2010
  54. Idiopathic eosinophilic masses of the gastrointestinal tract in dogs. J Vet Intern Med, 2009
  55. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol, 2009
  56. Brain penetration of ivermectin and selamectin in mdr1a,b P-glycoprotein- and bcrp- deficient knockout mice. J Vet Pharmacol Ther, 2009
  57. Natural allelic variants of bovine ATP-binding cassette transporter ABCG2: increased activity of the Ser581 variant and development of tools for the discovery of new ABCG2 inhibitors. Drug Metab Dispos, 2009
  58. Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice. Inflamm Res, 2008
  59. Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions. Pharm Res, 2008
  60. Assessment of antiepileptic drugs as substrates for canine P-glycoprotein. Am J Vet Res, 2007
  61. Ivermectin is an effective treatment for bovine cutaneous papillomatosis. Res Vet Sci, 2007
  62. [Modification of antitumor effect of vincristine by natural avermectins]. Antibiot Khimioter, 2004
  63. [Antitumor effect of natural avermectins]. Antibiot Khimioter, 2004
  64. Antitumor effect of avermectins. Eur J Pharmacol, 2004
  65. Effect of ivermectin on function of liver macrophages. Bull Exp Biol Med, 2003
  66. A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity. Biochemistry, 2003
  67. [Ivermectin inhibits activation of Kupffer cells induced by lipopolysaccharide toxin]. Antibiot Khimioter, 2003
  68. Could ivermectin have a synergic effect with albendazole in hydatidosis therapy? Parasitol Res, 2002
  69. [Proliferation and morphological differentiation of neurblastoma cells in cultured under the effect of avermectins]. Morfologiia, 2001
  70. Increased pathology incidence in the forestomach of rats maintained on a diet containing ivermectin and given a single dose of N-methyl-N1-nitro-N-nitrosoguanidine. J Environ Pathol Toxicol Oncol, 2001
  71. Insertion of a retroviral solo long terminal repeat in mdr-3 locus disrupts mRNA splicing in mice. Mamm Genome, 2000
  72. Selective cytostatic and neurotoxic effects of avermectins and activation of the GABAalpha receptors. Biosci Rep, 1999
  73. [Action of avermectins on lymphoid leukemia P-388 cells in vitro]. Antibiot Khimioter, 1999
  74. Cyclosporin A and trifluoperazine, two resistance-modulating agents, increase ivermectin neurotoxicity in mice. Pharmacol Toxicol, 1999
  75. Decreased biotolerability for ivermectin and cyclosporin A in mice exposed to potent P-glycoprotein inhibitors. Int J Cancer, 1995
  76. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest, 1995
Lab studies 151
  1. Experimental Assessment of the Time-Dependent Protective Effects of Ivermectin Against Atezolizumab-Induced Ovarian Toxicity and Impaired Reproductive Function. Toxics, 2026
  2. When drug repurposing backfires: antagonistic effects of ivermectin on cisplatin therapy in oral cancer. BMC Pharmacol Toxicol, 2026
  3. KPNβ1 and NKCC1 Modulators as Key Players in HCC: Possible Interventions in Cell Cycle Arrest and Apoptosis. Biofactors, 2026
  4. Ivermectin Inhibits Stress Granule Clearance by Blocking the De Novo Synthesis of Hsp70 in Neuroblastoma Cells. Cells, 2026
  5. Update to the Expression of Concern: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res, 2026
  6. Multi-Omics Identification of Vasculogenic Mimicry-Associated Molecular Subtypes in Hepatocellular Carcinoma for Prognostic Stratification and Therapeutic Response Prediction. Cancers (Basel), 2026
  7. A combination of artemisinin, moxidectin, and doxorubicin drugs can selectively and efficiently induce apoptosis in acute lymphoblastic and chronic myeloid leukemia cells in vitro and ex vivo. Med Oncol, 2026
  8. Tumor growth suppression of ivermectin in gastric cancer cell lines and primary gastric cancer organoids. J Gastrointest Oncol, 2026
  9. Direct comparison of efficacy of combining ivermectin versus five first-line chemotherapy drugs with recombinant methioninase against colon-cancer cells. Front Oncol, 2026
  10. Expression of Concern: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res, 2026
  11. A tti1 mutation in the Tel2-Tti1-Tti2 complex specifically eliminates the cellular function of Rad3ATR, but not that of other PIKKs in fission yeast. PLoS Genet, 2026
  12. Editorial Expression of Concern: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer, 2026
  13. Combination of ivermectin and metformin promotes autophagy in MCF‑7 cells by inhibiting phosphorylation of the PI3K/AKT/mTOR pathway. Oncol Rep, 2026
  14. Ivermectin-Benzimidazole Prescribing Following Celebrity Endorsement. JAMA Netw Open, 2026
  15. Correction: Characterisation of RNA guanine-7 methyltransferase (RNMT) using a small molecule approach. Biochem J, 2026
  16. Galectin-3 Binds to the Allosteric Site and Activates Integrins αvβ3, αIIbβ3, and α5β1, and Lactose Inhibits This Activation. Biomolecules, 2026
  17. Ivermectin inhibits ER, HER2, and TGF-β pathways in ER-positive and endocrine-resistant breast cancer cells. PLoS One, 2026
  18. Zinc finger protein 544 promotes hepatocellular carcinoma by generating an immunosuppressive tumor microenvironment. JHEP Rep, 2026
  19. Retraction: Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells. Biosci Rep, 2026
  20. The role of KPNA3 in multiple myeloma: implications for targeting nuclear import. Apoptosis, 2026
  21. Author Correction: Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer, 2026
  22. Inhibition of nuclear import suppresses androgen receptor action and overcomes resistance in prostate cancer. BMC Cancer, 2026
  23. HSP90AB1-Mediated Ubiquitin-Proteasome Degradation of ITGBL1 Promotes Osteosarcoma Progression by Inhibiting Endoplasmic Reticulum Stress-Induced Autophagy. Adv Sci (Weinh), 2026
  24. RETRACTION: Ivermectin Synergizes Sorafenib in Hepatocellular Carcinoma via Targeting Multiple Oncogenic Pathways. Pharmacol Res Perspect, 2026
  25. Galectin-3 binds to the RGD-binding site in a glycan-independent manner and to the allosteric site and activates integrins αvβ3, αIIbβ3, and α5β1. bioRxiv, 2026
  26. Biomimetic platelet-membrane camouflaged ivermectin nanocrystals for tumor homing and breast cancer management. Drug Deliv Transl Res, 2026
  27. Synergistic potential of Ivermectin and doxorubicin in oral squamous cell carcinoma: an in vitro investigation. BMC Pharmacol Toxicol, 2025
  28. Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal Fibroblasts. Anticancer Res, 2025
  29. Single-cell RNA sequencing reveals neutrophil differentiation-related genes for immunotherapy response prediction in colorectal cancer. BMC Cancer, 2025
  30. Purinergic Receptor Nanoimmunoamplifiers Potentiate Chemoimmunotherapy Efficacy in Hepatocellular Carcinoma. Biomater Res, 2025
  31. Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal Fibroblasts. Anticancer Res, 2025
  32. Ivermectin and dexamethasone combination induces apoptosis in SUP-B15 cell line. Narra J, 2025
  33. Ivermecatin induces cytotoxic effects in SUP-B15 cell line. Turk J Pediatr, 2025
  34. Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. Sci Adv, 2025
  35. Synergistic Antitumor Effects of Ivermectin and Metformin in Canine Breast Cancer via PI3K/AKT/mTOR Pathway Inhibition. Curr Issues Mol Biol, 2025
  36. Antiproliferative and Trypanocidal Activity of Ivermectin Bioconjugates. ACS Omega, 2025
  37. Ivermectin inhibits epithelial-to-mesenchymal transition via Wnt signaling in endocrine-resistant breast cancer cells. PLoS One, 2025
  38. Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression. ACS Biomater Sci Eng, 2025
  39. Selective Synergy of Ivermectin Combined With Recombinant Methioninase Against Colon-Cancer Cells in Contrast to Normal Fibroblasts. Anticancer Res, 2025
  40. Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin. Anticancer Res, 2025
  41. Ivermectin Combined With Recombinant Methioninase (rMETase) Synergistically Eradicates MiaPaCa-2 Pancreatic Cancer Cells. Anticancer Res, 2025
  42. Importin subunit beta-1 mediates ERK5 nuclear translocation, and its inhibition synergizes with ERK5 kinase inhibitors in reducing cancer cell proliferation. Mol Oncol, 2025
  43. Ivermectin Strengthens Paclitaxel Effectiveness in High-Grade Serous Carcinoma in 3D Cell Cultures. Pharmaceuticals (Basel), 2024
  44. Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells. Int J Mol Sci, 2024
  45. Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches. EPMA J, 2024
  46. Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of ABCB1 in Non-small Cell Lung Cancer. Anticancer Res, 2024
  47. Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway. Acta Biochim Biophys Sin (Shanghai), 2024
  48. Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer. Anal Chem, 2024
  49. Avermectin B1 mediates antitumor activity and induces autophagy in osteosarcoma through the AMPK/ULK1 signaling pathway. Cancer Chemother Pharmacol, 2024
  50. Inhaled Ivermectin-Loaded Lipid Polymer Hybrid Nanoparticles: Development and Characterization. Pharmaceutics, 2024
  51. Silencing of tropomodulin 1 inhibits acute myeloid leukemia cell proliferation and tumor growth by elevating karyopherin alpha 2-mediated autophagy. Pharmacol Res, 2024
  52. Overcoming flumatinib resistance in chronic myeloid leukaemia: Insights into cellular mechanisms and ivermectin's therapeutic potential. J Cell Mol Med, 2024
  53. Two new aromatic tenvermectins from mutant Streptomyces avermitilis HU02-06. J Antibiot (Tokyo), 2024
  54. Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma. Biomed Pharmacother, 2024
  55. Alendronate/lactoferrin-dual decorated lipid nanocarriers for bone-homing and active targeting of ivermectin and methyl dihydrojasmonate for leukemia. Biomater Adv, 2024
  56. Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis. Pharmaceuticals (Basel), 2024
  57. Biomass-Based, Dual Enzyme-Responsive Nanopesticides: Eco-friendly and Efficient Control of Pine Wood Nematode Disease. ACS Nano, 2024
  58. Drug repurposing-based nanoplatform via modulating autophagy to enhance chemo-phototherapy against colorectal cancer. J Nanobiotechnology, 2024
  59. Codelivery of ivermectin and methyl dihydrojasmonate in nanostructured lipid carrier for synergistic antileukemia therapy. Int J Pharm, 2024
  60. Lipid-Restricted Culture Media Reveal Unexpected Cancer Cell Sensitivities. ACS Chem Biol, 2024
  61. Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage. Anticancer Agents Med Chem, 2024
  62. Gene signatures to therapeutics: Assessing the potential of ivermectin against t(4;14) multiple myeloma. World J Clin Oncol, 2024
  63. Unexpected rearrangement of ivermectin in the synthesis of new derivatives with trypanocidal and antiplasmodial activities. Eur J Med Chem, 2024
  64. The Detrimental Effect of Pre-Treatment with Ivermectin on Myocardial Ischemia. Pharmacology, 2024
  65. Ivermectin induces nonprotective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells. Cancer Chemother Pharmacol, 2024
  66. Structural and molecular characterization of lopinavir and ivermectin as breast cancer resistance protein (BCRP/ABCG2) inhibitors. EXCLI J, 2023
  67. Targeting Heat Shock Protein 27 and Fatty Acid Oxidation Augments Cisplatin Treatment in Cisplatin-Resistant Ovarian Cancer Cell Lines. Int J Mol Sci, 2023
  68. Avermectin B1a Shows Potential Anti-Proliferative and Anticancer Effects in HCT-116 Cells via Enhancing the Stability of Microtubules. Curr Issues Mol Biol, 2023
  69. Topological Regulating Bismuth Nano-Semiconductor for Immunogenic Cell Death-Mediated Sonocatalytic Hyperthermia Therapy. Small, 2023
  70. Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors. J Control Release, 2023
  71. Eprinomectin: a derivative of ivermectin suppresses growth and metastatic phenotypes of prostate cancer cells by targeting the β-catenin signaling pathway. J Cancer Res Clin Oncol, 2023
  72. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. Cancer Lett, 2023
  73. Effect of doramectin on programmed cell death pathway in glioma cells. Clin Transl Oncol, 2023
  74. Ivermectin Augments the Anti-Cancer Activity of Pitavastatin in Ovarian Cancer Cells. Diseases, 2023
  75. Abamectin causes cardiac dysfunction in carp via inhibiting redox equilibrium and resulting in immune inflammatory response and programmed cell death. Environ Sci Pollut Res Int, 2023
  76. The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line. Int J Mol Sci, 2022
  77. Repurposing Ivermectin to augment chemotherapy's efficacy in osteosarcoma. Hum Exp Toxicol, 2022
  78. Ivermectin inhibits tumor metastasis by regulating the Wnt/β-catenin/integrin β1/FAK signaling pathway. Am J Cancer Res, 2022
  79. Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2. Viruses, 2022
  80. Extracellular binding sites of positive and negative allosteric P2X4 receptor modulators. Life Sci, 2022
  81. Ivermectin induces cell cycle arrest and caspase-dependent apoptosis in human urothelial carcinoma cells. Int J Med Sci, 2022
  82. Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma. Cancers (Basel), 2022
  83. Drug repurposing of ivermectin abrogates neutrophil extracellular traps and prevents melanoma metastasis. Front Oncol, 2022
  84. Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction. Front Pharmacol, 2022
  85. Integrated analysis reveals FOXA1 and Ku70/Ku80 as targets of ivermectin in prostate cancer. Cell Death Dis, 2022
  86. Ivermectin Enhanced Antitumor Activity of Resiquimod in a Co-Loaded Squalene Emulsion. J Pharm Sci, 2022
  87. Ivermectin-induced cell death of cervical cancer cells in vitro a consequence of precipitate formation in culture media. Toxicol Appl Pharmacol, 2022
  88. Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways. Pharmacol Res Perspect, 2022
  89. Doramectin inhibits glioblastoma cell survival via regulation of autophagy in vitro and in vivo. Int J Oncol, 2022
  90. Ivermectin accelerates autophagic death of glioma cells by inhibiting glycolysis through blocking GLUT4 mediated JAK/STAT signaling pathway activation. Environ Toxicol, 2022
  91. Ivermectin induces apoptosis of esophageal squamous cell carcinoma via mitochondrial pathway. BMC Cancer, 2021
  92. Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug against Schistosoma-Associated Bladder Cancer Targeting Protein Signaling: Computational Drug Repositioning Approach. Medicina (Kaunas), 2021
  93. Heat Shock Protein 27, a Novel Downstream Target of Collagen Type XI alpha 1, Synergizes with Fatty Acid Oxidation to Confer Cisplatin Resistance in Ovarian Cancer Cells. Cancers (Basel), 2021
  94. Ivermectin has New Application in Inhibiting Colorectal Cancer Cell Growth. Front Pharmacol, 2021
  95. Computational Drug Repositioning and Experimental Validation of Ivermectin in Treatment of Gastric Cancer. Front Pharmacol, 2021
  96. Ivermectin converts cold tumors hot and synergizes with immune checkpoint blockade for treatment of breast cancer. NPJ Breast Cancer, 2021
  97. SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells. J Mass Spectrom, 2021
  98. Development of a miRNA-controlled dual-sensing system and its application for targeting miR-21 signaling in tumorigenesis. Exp Mol Med, 2020
  99. Quantitative proteomics revealed energy metabolism pathway alterations in human epithelial ovarian carcinoma and their regulation by the antiparasite drug ivermectin: data interpretation in the context of 3P medicine. EPMA J, 2020
  100. Anti-parasite drug ivermectin can suppress ovarian cancer by regulating lncRNA-EIF4A3-mRNA axes. EPMA J, 2020
  101. Eprinomectin, a novel semi-synthetic macrocylic lactone is cytotoxic to PC3 metastatic prostate cancer cells via inducing apoptosis. Toxicol Appl Pharmacol, 2020
  102. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest, 2020
  103. Ivermectin induces autophagy-mediated cell death through the AKT/mTOR signaling pathway in glioma cells. Biosci Rep, 2019
  104. The PAK1-Stat3 Signaling Pathway Activates IL-6 Gene Transcription and Human Breast Cancer Stem Cell Formation. Cancers (Basel), 2019
  105. Ivermectin reverses the drug resistance in cancer cells through EGFR/ERK/Akt/NF-κB pathway. J Exp Clin Cancer Res, 2019
  106. Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway. Cell Prolif, 2019
  107. Suppressing ROS-TFE3-dependent autophagy enhances ivermectin-induced apoptosis in human melanoma cells. J Cell Biochem, 2019
  108. Oleic acid increases uptake and decreases the P-gp-mediated efflux of the veterinary anthelmintic Ivermectin. Drug Res (Stuttg), 2019
  109. Highlights of Skin Disease Education Foundations 42nd Annual Hawaii Dermatology Seminar. Semin Cutan Med Surg, 2018
  110. The Molecular Determinants of Small-Molecule Ligand Binding at P2X Receptors. Front Pharmacol, 2018
  111. Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun, 2018
  112. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget, 2017
  113. Increased Expression of a MicroRNA Correlates with Anthelmintic Resistance in Parasitic Nematodes. Front Cell Infect Microbiol, 2017
  114. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun, 2017
  115. Principles of Chemical Biology: Iron and CSCs, Histone Acylation sans Enzymes, Eliciting Silent Gene Clusters, and 2'-deoxy-ADPR as a Second Messenger. Cell Chem Biol, 2017
  116. Discovery of a Cryptic Antifungal Compound from Streptomyces albus J1074 Using High-Throughput Elicitor Screens. J Am Chem Soc, 2017
  117. Apoptosis of leukemia K562 and Molt-4 cells induced by emamectin benzoate involving mitochondrial membrane potential loss and intracellular Ca2+ modulation. Environ Toxicol Pharmacol, 2017
  118. New Avermectin Analogues from a Mutant Streptomyces avermectinius Strain. Chem Biodivers, 2017
  119. Long-Lasting WNT-TCF Response Blocking and Epigenetic Modifying Activities of Withanolide F in Human Cancer Cells. PLoS One, 2016
  120. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun, 2016
  121. Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer. Autophagy, 2016
  122. Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer. Cancer Res, 2016
  123. Drug Repositioning for Cancer Therapy Based on Large-Scale Drug-Induced Transcriptional Signatures. PLoS One, 2016
  124. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol, 2016
  125. Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep, 2015
  126. Autophagosome Proteins LC3A, LC3B and LC3C Have Distinct Subcellular Distribution Kinetics and Expression in Cancer Cell Lines. PLoS One, 2015
  127. DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis. Brain, 2015
  128. Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Mol Cancer Ther, 2015
  129. The river blindness drug Ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med, 2014
  130. HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Sci Rep, 2014
  131. Intestinal drug transport: ex vivo evaluation of the interactions between ABC transporters and anthelmintic molecules. J Vet Pharmacol Ther, 2014
  132. Hookworm-related cutaneous larva migrans in patients living in an endemic community in Brazil: immunological patterns before and after ivermectin treatmen. Eur J Microbiol Immunol (Bp), 2013
  133. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res, 2013
  134. In Vitro Effects of Ivermectin and Sulphadiazine on Toxoplasma gondii. Balkan Med J, 2013
  135. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm Drug Dispos, 2012
  136. High-throughput library screening identifies two novel NQO1 inducers in human lung cells. Am J Respir Cell Mol Biol, 2012
  137. Ivermectin versus malathion for head lice. N Engl J Med, 2010
  138. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by doramectin and nemadectin. J Pharm Pharmacol, 2010
  139. The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov Ther, 2010
  140. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther, 2009
  141. P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil. Arch Biochem Biophys, 2009
  142. Characterization of ionotrophic purinergic receptors in hepatocytes. Hepatology, 2008
  143. P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. J Vet Pharmacol Ther, 2007
  144. Avermectins inhibit multidrug resistance of tumor cells. Eur J Pharmacol, 2004
  145. Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun, 2004
  146. MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin. Eur J Pharmacol, 2003
  147. [Cytotoxic and cytostatic effect of avermectines on tumor cells in vitro]. Antibiot Khimioter, 2000
  148. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS, 2000
  149. Effects of the immunosuppressant FK506 on intracellular Ca2+ release and Ca2+ accumulation mechanisms. J Physiol, 2000
  150. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem Pharmacol, 1997
  151. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs, 1996
Reviews 25
  1. Drug repurposing as a promising therapeutic strategy against renal cell carcinoma. Cancer Chemother Pharmacol, 2026
  2. Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential. Pharmaceuticals (Basel), 2025
  3. Repurposing antimicrobials, disulfiram, and metformin for cancer therapy: Bridging mechanistic gaps through RNA sequencing. Eur J Pharmacol, 2025
  4. Ivermectin and non-parasitic disorders: An update. Curr Opin Pharmacol, 2025
  5. Repositioning anthelmintics for the treatment of inflammatory-based pathological conditions. Inflammopharmacology, 2025
  6. Re-examining the evidence that ivermectin induces a melanoma-like state in Xenopus embryos. Bioessays, 2024
  7. Ivermectin as a potential therapeutic strategy for glioma. J Neurosci Res, 2024
  8. TTT (Tel2-Tti1-Tti2) Complex, the Co-Chaperone of PIKKs and a Potential Target for Cancer Chemotherapy. Int J Mol Sci, 2023
  9. Novel strategies to reverse chemoresistance in colorectal cancer. Cancer Med, 2023
  10. Ivermectin: recent approaches in the design of novel veterinary and human medicines. Pharm Dev Technol, 2022
  11. Journal club Update on systemic therapies in paediatric dermatology. Eur J Dermatol, 2021
  12. ABCB1 in dermatology: roles in skin diseases and their treatment. J Mol Med (Berl), 2021
  13. Progress in Redirecting Antiparasitic Drugs for Cancer Treatment. Drug Des Devel Ther, 2021
  14. Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. Int J Mol Sci, 2020
  15. Targeting tumor hypoxia and mitochondrial metabolism with anti-parasitic drugs to improve radiation response in high-grade gliomas. J Exp Clin Cancer Res, 2020
  16. Old wine in new bottles: Drug repurposing in oncology. Eur J Pharmacol, 2020
  17. Doxycycline, salinomycin, monensin and ivermectin repositioned as cancer drugs. Bioorg Med Chem Lett, 2019
  18. Current state and outlook for drug repositioning anticipated in the field of ovarian cancer. J Gynecol Oncol, 2019
  19. Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. J Antibiot (Tokyo), 2018
  20. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. Am J Cancer Res, 2018
  21. Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations. J Antibiot (Tokyo), 2017
  22. P-glycoproteins and other multidrug resistance transporters in the pharmacology of anthelmintics: Prospects for reversing transport-dependent anthelmintic resistance. Int J Parasitol Drugs Drug Resist, 2012
  23. Role of ABC transporters in veterinary drug research and parasite resistance. Curr Drug Deliv, 2006
  24. [Parasitic diarrhea in eutrophic and malnourished children]. Med Trop (Mars), 2003
  25. Chronic diarrhoea in adult horses: a review of 51 referred cases. Vet Rec, 1992
Other papers, not yet read by us 7
  1. Antiparasitic agents in oncology: Innovative mechanisms, emerging evidence and clinical potential in cancer treatment. Eur J Med Chem, 2026
  2. RETRACTED: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. Anticancer Res, 2026
  3. Death caused by transdermal ivermectin poisoning: A case report and literature review. J Int Med Res, 2025
  4. Ivermectin in Cancer Treatment: Should Healthcare Providers Caution or Explore Its Therapeutic Potential? Curr Oncol Rep, 2025
  5. Antitumor effects of ivermectin at clinically feasible concentrations support its clinical development as a repositioned cancer drug. Cancer Chemother Pharmacol, 2020
  6. Anti-parasitic Drug Ivermectin Exhibits Potent Anticancer Activity Against Gemcitabine-resistant Cholangiocarcinoma In Vitro. Anticancer Res, 2019
  7. Ivermectin as an inhibitor of cancer stem‑like cells. Mol Med Rep, 2018

Checked against PubMed on 2026-10-28. Everything we know about Ivermectin